Company intelligence / Profile preview
Bold Therapeutics
Vancouver, British Columbia, Canadabold-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Bold Therapeutics has demonstrated positive safety and efficacy results for its lead asset BOLD-100 across several advanced gastrointestinal cancers. In completed and ongoing multinational Phase 2 trials, BOLD‑100 combined with standard-of-care chemotherapy showed improved progression-free survival, overall survival, disease control rates, and a favorable safety profile compared to historical controls. The company also presented data showing that BOLD‑100 can mitigate oxaliplatin-induced peripheral neuropathy—a significant side effect of current therapies—potentially expanding its clinical utility.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules (specifically metallotherapeutics; ruthenium-based small molecule therapeutics)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Ongoing academic collaboration with the University of Vienna’s Institute of Inorganic Chemistry led by Dr. Bernhard Keppler
Beyond the preview
Go deeper on Bold Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bold Therapeutics.